脑脊液淀粉样蛋白β及其他阿尔茨海默病生物标志物的昼夜振荡
Diurnal oscillation of CSF Aβ and other AD biomarkers.
作者信息
Lucey Brendan P, Fagan Anne M, Holtzman David M, Morris John C, Bateman Randall J
机构信息
Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St Louis, MO, 63110, USA.
出版信息
Mol Neurodegener. 2017 May 8;12(1):36. doi: 10.1186/s13024-017-0161-4.
Abstract
To assess stages of Alzheimer's disease (AD) pathogenesis and the efficacy of drugs during clinical trials, there has been immense interest in the field to establish baseline cerebrospinal fluid (CSF) concentrations for potential AD biomarkers such as amyloid-β (Aβ) and tau. Significant within-person variations in CSF Aβ concentrations over time found that this variation followed the sleep-wake cycle. A recent paper in Molecular Neurodegeneration reported the absence of diurnal variations in multiple classical and candidate AD biomarkers, such as soluble APP, Aβ, tau, p-tau, YKL-40, VILIP-1, or apolipoprotein E. This commentary addresses these apparently discordant results regarding the diurnal variability of APP and Aβ compared with the literature. Despite our concerns, we appreciate the authors' interest in this important topic and contribution to improve our knowledge about the factors influencing Aβ diurnal variation.
摘要
为了在临床试验期间评估阿尔茨海默病（AD）发病机制的阶段以及药物疗效，该领域对建立潜在AD生物标志物（如淀粉样蛋白-β（Aβ）和tau）的脑脊液（CSF）基线浓度有着浓厚兴趣。随着时间的推移，脑脊液Aβ浓度存在显著的个体内差异，发现这种差异遵循睡眠-觉醒周期。《分子神经退行性变》最近发表的一篇论文报道，多种经典和候选AD生物标志物（如可溶性APP、Aβ、tau、p-tau、YKL-40、VILIP-1或载脂蛋白E）不存在昼夜变化。这篇评论讨论了与文献相比，关于APP和Aβ昼夜变异性这些明显不一致的结果。尽管我们有所担忧，但我们赞赏作者对这一重要主题的关注以及为增进我们对影响Aβ昼夜变化因素的了解所做出的贡献。
相似文献
1
Diurnal oscillation of CSF Aβ and other AD biomarkers.脑脊液淀粉样蛋白β及其他阿尔茨海默病生物标志物的昼夜振荡
Mol Neurodegener. 2017 May 8;12(1):36. doi: 10.1186/s13024-017-0161-4.
2
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系：一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
3
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.脑脊液中阿尔茨海默病的经典及候选生物标志物无昼夜变化。
Mol Neurodegener. 2016 Sep 7;11(1):65. doi: 10.1186/s13024-016-0130-3.
4
Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.采用基于微球的 xMAP 多重分析技术同步分析脑脊液生物标志物，用于阿尔茨海默病的早期检测。
Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6.
5
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.阿尔茨海默病标准化脑脊液生物标志物在澳大利亚成像、生物标志物和生活方式（AIBL）研究中经PET淀粉样β蛋白特征化的受试者中得到验证。
J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.
6
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.在常规实践中，将β淀粉样蛋白42（Aβ₄₂）/β淀粉样蛋白40（Aβ₄₀）比值与脑脊液生物标志物磷酸化tau蛋白（P-tau）和Aβ₄₂一起使用，可提高阿尔茨海默病病理生理过程的证据水平。
J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.
7
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.载脂蛋白 E 基因型与阿尔茨海默病脑脊液生物标志物的诊断准确性。
JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.
8
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.在OPTIMA队列中，脑脊液生物标志物可将经尸检确诊的阿尔茨海默病与其他痴呆症及健康对照区分开来。
J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.
9
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.早期阿尔茨海默病中神经退行性变的脑脊液标志物与脑萎缩速度。
JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.
10
Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.脑脊液 Aβ(1-42)和 τ 蛋白作为阿尔茨海默病生物标志物的临床实用性和分析挑战。
Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21.
引用本文的文献
1
Soluble VCAM-1 May Serve as a Pharmacodynamic CSF Marker to Monitor BACE2 Activity in Non-Human Primates.可溶性血管细胞黏附分子-1可作为药效学脑脊液标志物，用于监测非人灵长类动物中的β-分泌酶2活性。
Mol Cell Proteomics. 2025 Jun 4;24(7):101012. doi: 10.1016/j.mcpro.2025.101012.
2
Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic.血浆p-tau217和Aβ42/40生物标志物在门诊记忆诊所的诊断性能。
Alzheimers Dement. 2025 Jun;21(6):e70316. doi: 10.1002/alz.70316.
3
P-tau217 and other blood biomarkers of dementia: variation with time of day.P-tau217 和其他痴呆症血液生物标志物：随时间的变化。
Transl Psychiatry. 2024 Sep 13;14(1):373. doi: 10.1038/s41398-024-03084-7.
4
Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.联合脑脊液和 PI-2620 tau-PET 进行基于生物标志物的阿尔茨海默病和 4R-tau 病的分层。
Alzheimers Dement. 2024 Oct;20(10):6896-6909. doi: 10.1002/alz.14185. Epub 2024 Sep 12.
5
Amyloid-β but not tau accumulation is strongly associated with longitudinal cognitive decline.淀粉样蛋白-β而非 tau 积聚与纵向认知能力下降密切相关。
CNS Neurosci Ther. 2024 Jul;30(7):e14860. doi: 10.1111/cns.14860.
6
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.采样时间对阿尔茨海默病生物标志物的脑脊液和血浆水平的影响。
Alzheimers Res Ther. 2024 Jun 22;16(1):132. doi: 10.1186/s13195-024-01503-x.
7
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.细胞外囊泡研究的最低信息要求（MISEV2023）：从基础到先进方法。
J Extracell Vesicles. 2024 Feb;13(2):e12404. doi: 10.1002/jev2.12404.
8
Understanding the Episodic Memory and Executive Functioning Axis Impairment in MCI Patients: A Multicenter Study in Comparison with CSF Biomarkers.了解轻度认知障碍（MCI）患者的情景记忆和执行功能轴损伤：一项与脑脊液生物标志物对比的多中心研究
Biomedicines. 2023 Nov 26;11(12):3147. doi: 10.3390/biomedicines11123147.
9
Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation.纳米递药脑活素联合抗淀粉样β肽、磷酸化tau 和肿瘤坏死因子α抗体可诱导睡眠剥夺加重的阿尔茨海默病脑病理的神经保护作用。
Adv Neurobiol. 2023;32:3-53. doi: 10.1007/978-3-031-32997-5_1.
10
The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130.阿尔茨海默病相关蛋白酶 BACE1 通过脱落受体 gp130 调节神经元 IL-6 信号转导。
Mol Neurodegener. 2023 Feb 21;18(1):13. doi: 10.1186/s13024-023-00596-6.
本文引用的文献
1
Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.β-淀粉样蛋白在中枢神经系统中的动力学与昼夜节律的相关性研究。
JAMA Neurol. 2017 Feb 1;74(2):207-215. doi: 10.1001/jamaneurol.2016.4202.
2
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.脑脊液中阿尔茨海默病的经典及候选生物标志物无昼夜变化。
Mol Neurodegener. 2016 Sep 7;11(1):65. doi: 10.1186/s13024-016-0130-3.
3
An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.对通过腰椎穿刺和留置腰椎导管收集的脑脊液淀粉样蛋白-β浓度的个体内变异性进行的综合多研究分析。
Alzheimers Res Ther. 2015 Jul 29;7(1):53. doi: 10.1186/s13195-015-0136-z. eCollection 2015.
4
Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation.阿尔茨海默病脑脊液生物标志物分析中的分析前混杂因素：昼夜变化问题
Front Neurol. 2015 Jun 29;6:143. doi: 10.3389/fneur.2015.00143. eCollection 2015.
5
Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.人类中枢神经系统中可溶性淀粉样前体蛋白代谢物的昼夜节律。
PLoS One. 2014 Mar 19;9(3):e89998. doi: 10.1371/journal.pone.0089998. eCollection 2014.
6
β-amyloid dynamics in human plasma.人血浆中的β-淀粉样蛋白动力学
Arch Neurol. 2012 Dec;69(12):1591-7. doi: 10.1001/archneurol.2012.18107.
7
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology.阿尔茨海默病病理小鼠睡眠-觉醒周期和β-淀粉样蛋白昼夜波动的破坏。
Sci Transl Med. 2012 Sep 5;4(150):150ra122. doi: 10.1126/scitranslmed.3004291.
8
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels.人类脑脊液采样频率对淀粉样蛋白-β水平的影响。
Alzheimers Dement. 2012 Jul;8(4):295-303. doi: 10.1016/j.jalz.2011.05.900. Epub 2011 Nov 2.
9
Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.年龄和淀粉样蛋白沉积对人类中枢神经系统中Aβ动力学的影响。
Arch Neurol. 2012 Jan;69(1):51-8. doi: 10.1001/archneurol.2011.235. Epub 2011 Sep 12.
10
Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.阿尔茨海默病患者和健康老年志愿者脑脊液生物标志物的时间变异性。
Neurobiol Aging. 2012 Apr;33(4):831.e1-9. doi: 10.1016/j.neurobiolaging.2011.07.008. Epub 2011 Aug 31.
Zotero 插件